Clarence Gill, MD
Interventional Cardiology · Huntsville, ALNPI 1477970762
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Abbott at 53.7% of the total. Reporting peaked in 2022 at $5,888 and has fallen 87.9% since, to $715 in 2025.
Across 171 payments — averaging $77.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Inari Medical, Inc.$2K
- Abiomed$1K
- Boston Scientific$617
- Shockwave Medical, Inc$354
- Cardiovascular Systems Inc.$233
- plus $1K from 16 others
What the payments were for
- Travel & lodging$7135%
- Food & beverage$12,44294%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 72 | $7,107 |
| Inari Medical, Inc. | 22 | $2,209 |
| Abiomed | 12 | $1,338 |
| Boston Scientific | 9 | $617 |
| Shockwave Medical, Inc | 3 | $354 |
| Cardiovascular Systems Inc. | 2 | $233 |
| E.r. Squibb & Sons, L.L.C. | 3 | $190 |
| Pfizer | 9 | $168 |
| AstraZeneca | 5 | $165 |
| Amgen | 8 | $143 |
| Astellas Pharma US Inc | 3 | $138 |
| Novartis | 5 | $111 |
| Boehringer Ingelheim | 3 | $87 |
| Cvrx, Inc. | 1 | $68 |
| Johnson & Johnson | 2 | $60 |
| Merck | 3 | $56 |
| Medtronic | 3 | $55 |
| Scpharmaceuticals Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 1 | $38 |
| United Therapeutics Corporation | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISOR$2,443
- FLOWTRIEVER CATHETER, S$1,736
- CT THROMBECTOMY SYSTEM KIT$1,280
- Impella$1,226
- Ensite Cardiac Mapping System$933
- Advisor Catheter$870
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$354
- MERLIN@HOME$281
- Diamondback Coronary$196
- Agilis HisPro$153
- WATCHMAN Access System$152
- CardioMEMS HF System$148
- AGILIS$133
- AVEIR$125
- AVVIGO Guidance System$120
- PERCLOSE PROGLIDE$109
- RESONATE EL ICD VR$106
- AMPLATZER$100
How this compares
$13,245 in reported general payments places this provider in the 75th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $132,027 |
| EntrestoSacubitril/Valsartan | 53 | $53,335 |
| FarxigaDapagliflozin Propanediol | 35 | $31,632 |
| JardianceEmpagliflozin | 19 | $21,391 |
| XareltoRivaroxaban | 34 | $21,381 |
| Prasugrel Hcl | 87 | $6,873 |
| Metoprolol Succinate | 159 | $2,440 |
| Atorvastatin Calcium | 156 | $2,187 |
| ClopidogrelClopidogrel Bisulfate | 116 | $1,372 |
| Carvedilol | 115 | $998 |
| Losartan Potassium | 80 | $831 |
| Amiodarone Hcl | 47 | $750 |
| Ezetimibe | 12 | $588 |
| Valsartan | 16 | $507 |
| Nifedipine ErNifedipine | 13 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $132,027135 claims |
| NovartisEntresto | $111 | $53,33553 claims |
| AstraZenecaFarxiga | $165 | $31,63235 claims |
| Boehringer IngelheimJardiance | $87 | $21,39119 claims |
| Johnson & JohnsonXarelto | $60 | $21,38134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Alejandro VasquezHuntsville$45K
- David DrenningHuntsville$31K
- Victor OkunrintemiHuntsville$12K
- Henry ChenHuntsville$8K
- Mihir KanitkarHuntsville$7K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.